CoChat
Sign Up
Cited by 36MicroRNA in disease regulationCholesterol and Lipid MetabolismLipid metabolism and disorders

miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches

Open access
Price, Nathan L, Goedeke, Leigh, Suárez, Yajaira, Fernández‐Hernando, Carlos·2021·EMBO Molecular Medicine
DOI 10.15252/emmm.202012606PMC PMC8103095
Open this paper in CoChat — free account

Abstract

miRNAs have emerged as critical regulators of nearly all biologic processes and important therapeutic targets for numerous diseases. However, despite the tremendous progress that has been made in this field, many misconceptions remain among much of the broader scientific community about the manner in which miRNAs function. In this review, we focus on miR‐33, one of the most extensively studied miRNAs, as an example, to highlight many of the advances that have been made in the miRNA field and the hurdles that must be cleared to promote the development of miRNA‐based therapies. We discuss how the generation of novel animal models and newly developed experimental techniques helped to elucidate the specialized roles of miR‐33 within different tissues and begin to define the specific mechanisms by which miR‐33 contributes to cardiometabolic diseases including obesity and atherosclerosis. This review will summarize what is known about miR‐33 and highlight common obstacles in the miRNA field and then describe recent advances and approaches that have allowed researchers to provide a more complete picture of the specific functions of this miRNA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202012606

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 104 · Cited by 36

Research works printed but not linked: 83

  1. Amaar YG, Reeves ME (2019) RASSF1C regulates miR‐33a and EMT marker gene expression in lung cancer cells. Oncotarget 10: 123– 132 30719208 PMC6349430
  2. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350– 355 15372042
  3. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215– 233 19167326 PMC3794896
  4. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570– 2581 12020339
  5. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ (2003) Dicer is essential for mouse development. Nat Genet 35: 215– 217 14528307
  6. Bornfeldt KE, Tabas I (2011) Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14: 575– 585 22055501 PMC3217209
  7. Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, Lusis AJ, Collins A, Hseuh WA, Collins JL et al (2007) Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 117: 2337– 2346 17657314 PMC1924496
  8. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane‐bound transcription factor. Cell 89: 331– 340 9150132
  9. Brown MS, Ye J, Goldstein JL (2010) Medicine. HDL miR‐ed down by SREBP introns. Science 328: 1495– 1496 20558698 PMC2936826
  10. Cai L, Hecker TL, Layne JD, Wang Z, Paxton SM, Burkett CR, Keenan TE, Meshram N, Kelley MR, Ching‐Yi H et al (2019) Impact of MicroRNA‐33a/b antagonism on atherosclerosis regression and stabilization in a nonhuman primate model. In Gordon Conference: From Molecular and Cellular Insights to Therapeutic Approaches in Atherosclerosis (Newry, ME).
  11. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM et al (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518: 107– 110 25409146 PMC4367962
  12. Cheng X, Li J, Guo D (2018) SCAP/SREBPs are central players in lipid metabolism and novel metabolic targets in cancer therapy. Curr Top Med Chem 18: 484– 493 29788888 PMC6214187
  13. Cirera‐Salinas D, Pauta M, Allen RM, Salerno AG, Ramírez CM, Chamorro‐Jorganes A, Wanschel AC, Lasuncion MA, Morales‐Ruiz M, Suarez Y et al (2012) Mir‐33 regulates cell proliferation and cell cycle progression. Cell Cycle 11: 922– 933 22333591 PMC3323796
  14. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro J‐M, Paterniti JR, Mangelsdorf DJ et al (2001) Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 98: 2610– 2615 11226287 PMC30186
  15. DeBose‐Boyd RA, Ye J (2018) SREBPs in lipid metabolism, insulin signaling, and beyond. Trends Biochem Sci 43: 358– 368 29500098 PMC5923433
  16. Distel E, Barrett TJ, Chung K, Girgis NM, Parathath S, Essau CC, Murphy AJ, Moore KJ, Fisher EA (2014) miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. Circ Res 115: 759– 769 25201910 PMC4194153
  17. Gore MO, McGuire DK, Lingvay I, Rosenstock J (2015) Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. Curr Cardiol Rep 17: 607 26031671
  18. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229– 234 9673301
  19. Harfe BD, McManus MT, Mansfield JH, Hornstein E, Tabin CJ (2005) The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci USA 102: 10898– 10903 16040801 PMC1182454
  20. Helwak A, Tollervey D (2014) Mapping the miRNA interactome by cross‐linking ligation and sequencing of hybrids (CLASH). Nat Protoc 9: 711– 728 24577361 PMC4033841
  21. Hennessy EJ, van Solingen C, Scacalossi KR, Ouimet M, Afonso MS, Prins J, Koelwyn GJ, Sharma M, Ramkhelawon B, Carpenter S et al (2019) The long noncoding RNA CHROME regulates cholesterol homeostasis in primates. Nat Metab 1: 98– 110 31410392 PMC6691505
  22. Herrera‐Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, Gonzalez S (2010) miR‐33‐mediated downregulation of p53 controls hematopoietic stem cell self‐renewal. Cell Cycle 9: 3277– 3285 20703086
  23. Ho PC, Chang KC, Chuang YS, Wei LN (2011) Cholesterol regulation of receptor‐interacting protein 140 via microRNA‐33 in inflammatory cytokine production. FASEB J 25: 1758– 1766 21285396 PMC3079307
  24. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, Horiguchi M, Nakamura T, Chonabayashi K, Hishizawa M et al (2012) MicroRNA‐33 deficiency reduces the progression of atherosclerotic plaque in ApoE‐/‐ mice. J Am Heart Assoc 1: e003376 23316322 PMC3540673
  25. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y et al (2010) MicroRNA‐33 encoded by an intron of sterol regulatory element‐binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 107: 17321– 17326 20855588 PMC2951399
  26. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125– 1131 11994399 PMC150968
  27. Huang Y, Zhang J, Shao H, Liu J, Jin M, Chen J, Zhao H (2018) miR‐33a mediates the anti‐tumor effect of lovastatin in osteosarcoma by targeting CYR61. Cell Physiol Biochem 51: 938– 948 30466075
  28. Joseph Sb, McKilligin E, Pei L, Watson Ma, Collins Ar, Laffitte Ba, Chen M, Noh G, Goodman J, Hagger Gn et al (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99: 7604– 7609 12032330 PMC124297
  29. Jovasevic V, Corcoran KA, Leaderbrand K, Yamawaki N, Guedea AL, Chen HJ, Shepherd GM, Radulovic J (2015) GABAergic mechanisms regulated by miR‐33 encode state‐dependent fear. Nat Neurosci 18: 1265– 1271 26280760 PMC4880671
  30. Karatas OF, Wang J, Shao L, Ozen M, Zhang Y, Creighton CJ, Ittmann M (2017) miR‐33a is a tumor suppressor microRNA that is decreased in prostate cancer. Oncotarget 8: 60243– 60256 28947967 PMC5601135
  31. Klein Geltink RI, O’Sullivan D, Corrado M, Bremser A, Buck MD, Buescher JM, Firat E, Zhu X, Niedermann G, Caputa G et al (2017) Mitochondrial priming by CD28. Cell 171: 385– 397.e11 28919076 PMC5637396
  32. Koyama S, Horie T, Nishino T, Baba O, Sowa N, Miyasaka Y, Kuwabara Y, Nakao T, Nishiga M, Nishi H et al (2019) Identification of differential roles of microRNA‐33a and ‐33b during atherosclerosis progression with genetically modified mice. J Am Heart Assoc 8: e012609 31242815 PMC6662357
  33. Lai L, Azzam KM, Lin W‐C, Rai P, Lowe JM, Gabor KA, Madenspacher JH, Aloor JJ, Parks JS, Näär AM et al (2016) MicroRNA‐33 regulates the innate immune response via ATP Binding cassette transporter‐mediated remodeling of membrane microdomains. J Biol Chem 291: 19651– 19660 27471270 PMC5016698
  34. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin‐4 encodes small RNAs with antisense complementarity to lin‐14. Cell 75: 843– 854 8252621
  35. Li T, Francl JM, Boehme S, Chiang JY (2013) Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha‐hydroxylase/steroid response element‐binding protein 2/microRNA‐33a axis in mice. Hepatology 58: 1111– 1121 23536474 PMC3735649
  36. Liu D, Tan Q, Zhu J, Zhang Y, Xue Y, Song Y, Liu Y, Wang Q, Lai L (2019) MicroRNA‐33/33* inhibit the activation of MAVS through AMPK in antiviral innate immunity. Cell Mol Immunol 10.1038/s41423-019-0326-x PMC8167167 31767975 · DOI
  37. Lv W, Fan F, Wang Y, Gonzalez‐Fernandez E, Wang C, Yang L, Booz GW, Roman RJ (2018) Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics 50: 20– 34 29127220 PMC5866411
  38. Marquart TJ, Allen RM, Ory DS, Baldan A (2010) miR‐33 links SREBP‐2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 107: 12228– 12232 20566875 PMC2901433
  39. Naar AM (2018) miR‐33: A Metabolic Conundrum. Trends Endocrinol Metab 29: 667– 668 29692333 PMC6151149
  40. Nguyen MA, Wyatt H, Susser L, Geoffrion M, Rasheed A, Duchez AC, Cottee ML, Afolayan E, Farah E, Kahiel Z et al (2019) Delivery of microRNAs by chitosan nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo. ACS Nano 13: 6491– 6505 31125197
  41. Nishino T, Horie T, Baba O, Sowa N, Hanada R, Kuwabara Y, Nakao T, Nishiga M, Nishi H, Nakashima Y et al (2018). SREBF1/MicroRNA‐33b axis exhibits potent effect on unstable atherosclerotic plaque formation in vivo. Arterioscler Thromb Vasc Biol 38: 2460– 2473. 30354203
  42. Oram JF (2000) Tangier disease and ABCA1. Biochim Biophys Acta 1529: 321– 330 11111099
  43. Orom UA, Lund AH (2007) Isolation of microRNA targets using biotinylated synthetic microRNAs. Methods 43: 162– 165 17889804
  44. Ouimet M, Barrett TJ, Fisher EA (2019) HDL and reverse cholesterol transport. Circ Res 124: 1505– 1518 31071007 PMC6813799
  45. Ouimet M, Ediriweera H, Afonso MS, Ramkhelawon B, Singaravelu R, Liao X, Bandler RC, Rahman K, Fisher EA, Rayner KJ et al (2017) microRNA‐33 regulates macrophage autophagy in atherosclerosis. Arterioscler Thromb Vasc Biol 37: 1058– 1067 28428217 PMC5494696
  46. Ouimet M, Hennessy EJ, van Solingen C, Koelwyn GJ, Hussein MA, Ramkhelawon B, Rayner KJ, Temel RE, Perisic L, Hedin U et al (2016a) miRNA targeting of oxysterol‐binding protein‐like 6 regulates cholesterol trafficking and efflux. Arterioscler Thromb Vasc Biol 36: 942– 951 26941018 PMC4850101
  47. Ouimet M, Koster S, Sakowski E, Ramkhelawon B, van Solingen C, Oldebeken S, Karunakaran D, Portal‐Celhay C, Sheedy FJ, Ray TD et al (2016b) Mycobacterium tuberculosis induces the miR‐33 locus to reprogram autophagy and host lipid metabolism. Nat Immunol 17: 677– 686 27089382 PMC4873392
  48. Peet DJ, Janowski BA, Mangelsdorf DJ (1998) The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev 8: 571– 575 9794827
  49. Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N‐acetyl galactosamine improves potency 10‐fold in mice. Nucleic Acids Res 42: 8796– 8807 24992960 PMC4117763
  50. Price NL, Holtrup B, Kwei SL, Wabitsch M, Rodeheffer M, Bianchini L, Suarez Y, Fernandez‐Hernando C (2016) SREBP‐1c/MicroRNA 33b genomic loci control adipocyte differentiation. Mol Cell Biol 36: 1180– 1193 26830228 PMC4800797
  51. Price NL, Miguel V, Ding W, Singh AK, Malik S, Rotllan N, Moshnikova A, Toczek J, Zeiss C, Sadeghi MM et al (2019a). Genetic deficiency or pharmacological inhibition of miR‐33 protects from kidney fibrosis. JCI Insight 4: e131102 PMC6948871 31613798
  52. Price NL, Rotllan N, Canfrán‐Duque A, Zhang X, Pati P, Arias N, Moen J, Mayr M, Ford DA, Baldán Á et al (2017) Genetic dissection of the impact of miR‐33a and miR‐33b during the progression of atherosclerosis. Cell Rep 21: 1317– 1330 29091769 PMC5687841
  53. Price NL, Rotllan N, Zhang X, Canfran‐Duque A, Nottoli T, Suarez Y, Fernandez‐Hernando C (2019b) Specific disruption of Abca1 targeting largely mimics the effects of miR‐33 knockout on macrophage cholesterol efflux and atherosclerotic plaque development. Circ Res 124: 874– 880 30707082 PMC6417928
  54. Price NL, Zhang X, Fernandez‐Tussy P, Singh AK, Burnap SA, Rotllan N, Goedeke L, Sun J, Canfran‐Duque A, Aryal B et al (2021) Loss of hepatic miR‐33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis. Proc Natl Acad Sci USA 118: e2006478118 33495342 PMC7865172
  55. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X et al (2011a) Inhibition of miR‐33a/b in non‐human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478: 404– 407 22012398 PMC3235584
  56. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez‐Hernando C (2010) MiR‐33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570– 1573 20466885 PMC3114628
  57. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ (2000) Regulation of mouse sterol regulatory element‐binding protein‐1c gene (SREBP‐1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14: 2819– 2830 11090130 PMC317055
  58. Rodriguez A, Griffiths‐Jones S, Ashurst JL, Bradley A (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res 14: 1902– 1910 15364901 PMC524413
  59. Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez‐Hernando C (2013) Therapeutic silencing of microRNA‐33 inhibits the progression of atherosclerosis in Ldlr‐/‐ mice–brief report. Arterioscler Thromb Vasc Biol 33: 1973– 1977 23702658 PMC4157595
  60. Rottiers V, Naar AM (2012) MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13: 239– 250 22436747 PMC4021399
  61. Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, Sinha S, Goody RJ, Lawrence Ms, deLemos As et al (2013) Pharmacological inhibition of a microRNA family in nonhuman primates by a seed‐targeting 8‐mer antimiR. Sci Transl Med 5: 212ra162 PMC4033576 24259050
  62. Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García‐Milian R, Mehta S et al (2019) Suppressing miR‐21 activity in tumor‐associated macrophages promotes an antitumor immune response. J Clin Invest 129: 5518– 5536 31710308 PMC6877327
  63. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ et al (2000) Role of LXRs in control of lipogenesis. Genes Dev 14: 2831– 2838 11090131 PMC317060
  64. Sene A, Khan A, Cox D, Nakamura R, Santeford A, Kim B, Sidhu R, Onken M, Harbour J, Hagbi‐Levi S et al (2013) Impaired cholesterol efflux in senescent macrophages promotes age‐related macular degeneration. Cell Metab 17: 549– 561 23562078 PMC3640261
  65. Shao F, Wang X, Yu J, Jiang H, Zhu B, Gu Z (2014) Expression of miR‐33 from an SREBF2 intron targets the FTO gene in the chicken. PLoS One 9: e91236 24626192 PMC3953336
  66. Shao F, Wang X, Yu J, Shen K, Qi C, Gu Z (2019) Expression of miR‐33 from an SREBP2 intron inhibits the expression of the fatty acid oxidation‐regulatory genes CROT and HADHB in chicken liver. Br Poult Sci 60: 115– 124 30698464
  67. Tall AR, Yvan‐Charvet L, Terasaka N, Pagler T, Wang N (2008) HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 7: 365– 375 18460328
  68. Tang CY, Man XF, Guo Y, Tang HN, Tang J, Zhou CL, Tan SW, Wang M, Zhou HD (2017) IRS‐2 partially compensates for the insulin signal defects in IRS‐1(‐/‐) mice mediated by miR‐33. Mol Cells 40: 123– 132 28190325 PMC5339503
  69. Tao Y, Xu S, Wang J, Xu Li, Zhang C, Chen K, Lian Z, Zhou J, Xie H, Zheng S et al (2020) Delivery of microRNA‐33 antagomirs by mesoporous silica nanoparticles to ameliorate lipid metabolic disorders. Front Pharmacol 11: 921 32848718 PMC7419650
  70. Tarling EJ, Ahn H, de Aguiar Vallim TQ (2015) The nuclear receptor FXR uncouples the actions of miR‐33 from SREBP‐2. Arterioscler Thromb Vasc Biol 35: 787– 795 25593129 PMC4376635
  71. Tian F, Wei H, Tian H, Qiu Y, Xu J (2016) miR‐33a is downregulated in melanoma cells and modulates cell proliferation by targeting PCTAIRE1. Oncol Lett 11: 2741– 2746 27073545 PMC4812543
  72. Vergnes L, Chin RG, de Aguiar Vallim T, Fong LG, Osborne TF, Young SG, Reue K (2016) SREBP‐2‐deficient and hypomorphic mice reveal roles for SREBP‐2 in embryonic development and SREBP‐1c expression. J Lipid Res 57: 410– 421 26685326 PMC4766990
  73. Wang H, Hu Z, Shi F, Dong J, Dang L, Wang Y, Sun Z, Zhou H, Zhang S, Cao X et al (2018) Osteoblast‐targeted delivery of miR‐33‐5p attenuates osteopenia development induced by mechanical unloading in mice. Cell Death Dis 9: 170 29415986 PMC5833703
  74. Wang X, Li X, Huang B, Yang L, Chen K, Zhao D, Luo X, Wang Y (2020) Downregulation of miR‐33 has protective effect against Abeta(2)(5)(‐)(3)(5)‐Induced Injury in SH‐SH‐SY5Y cells. Med Sci Monit 26: e921026 32119650 PMC7067051
  75. Weihua Z, Guorong Z, Xiaolong C, Weizhan L (2020) MiR‐33a functions as a tumor suppressor in triple‐negative breast cancer by targeting EZH2. Cancer Cell Int 20: 85 32206036 PMC7079399
  76. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin‐14 by lin‐4 mediates temporal pattern formation in C. elegans. Cell 75: 855– 862 8252622
  77. Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, Verchere CB, Hayden MR (2012) miR‐33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 61: 653– 658 22315319 PMC3282802
  78. Xu G, Wei X, Tu Q, Zhou C (2020) Up‐regulated microRNA‐33b inhibits epithelial‐mesenchymal transition in gallbladder cancer through down‐regulating CROCC. Biosci Rep 40: BSR20190108 31799620 PMC6954365
  79. Zhang C, Zhang Y, Ding W, Lin Y, Huang Z, Luo Q (2015) MiR‐33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1. Protein Cell 6: 881– 889 26507842 PMC4656205
  80. Zhang X, Rottlan N, Canfran‐Duque A, Toczek J, Moshnikova A, Malik S, Price N, Araldi E, Zhong W, Sadeghi M et al (2020) Targeted suppression of microRNA‐33 in lesional macrophages using pH low‐insertion peptides (pHLIP) improves atherosclerotic plaque regression. Res Square 10.21203/rs.3.rs-92252/v1 [PREPRINT] · DOI
  81. Zhao GJ, Tang SL, Lv YC, Ouyang XP, He PP, Yao F, Tang YY, Zhang M, Tang YL, Tang DP et al (2014) NF‐kappaB suppresses the expression of ATP‐binding cassette transporter A1/G1 by regulating SREBP‐2 and miR‐33a in mice. Int J Cardiol 171: e93– 95 24360166
  82. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D (2007) Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA‐1‐2. Cell 129: 303– 317 17397913
  83. Zhu T, Corraze G, Plagnes‐Juan E, Skiba‐Cassy S (2020) Cholesterol metabolism regulation mediated by SREBP‐2, LXRalpha and miR‐33a in rainbow trout (Oncorhynchus mykiss) both in vivo and in vitro. PLoS One 15: e0223813 32109243 PMC7048274

Authors
Price, N. L., Goedeke, L., Suárez, Y., & Fernández‐Hernando, C.
Affiliations
Yale University (US)
ORCID
Venue
EMBO Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2021-05-03
Volume
13
Issue
5
Pages
e12606-e12606
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
DOI
10.15252/emmm.202012606
PMC
PMC8103095
OpenAlex
W3158825162
Cited by
36
References
104
Citations by year
2026: 5 · 2025: 9 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 2
FWCI
0.66
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • HHS|NIH|National Heart, Lung, and Blood Institute (R35HL135820, R01HL135012, R01HL105945, K99HL150234)
  • HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (1K01DK120794)
  • American Heart Association (16EIA27550005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
miR-33, microRNA, cardiometabolic disease, obesity, atherosclerosis, animal models, miRNA-based therapy, lipid metabolism
MeSH terms
Animals, Humans, Models, Animal, MicroRNAs, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review